A Phase 2 interventional study of LAM-002A and Placebo in Amyotrophic Lateral Sclerosis and ALS, sponsored by IRulya Therapeutics Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by IRulya Therapeutics Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 225th largest by enrollment of the 307 interventional ones that give a count, is one of 33 that started in 2021, is one of 89 in phase 2, and was the 311th registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–80
Cognixion · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
Neuralink Corp · Sites in United States
Ages 18+
Biogen · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
440 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 139 · Phase 3 48 · Phase 4 1
First in 1982; this study’s year is marked. 33 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 33 across the 307 interventional studies, 100 across the 121 observational. Of the 277 that completed or were terminated, 102 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
163 of 440 have an industry lead sponsor. The 10 most frequent:
IRulya Therapeutics Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
IRulya Therapeutics Inc. has 1 study filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
41 of the studies in Amyotrophic Lateral Sclerosis with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161999Phase 3Coya TherapeuticsStudy of COYA 302 for the Treatment of ALS | 2027-04 |
| NCT04057898Phase 3MediciNovaEvaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | 2027-04 |
| NCT04297683Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Master Protocol | 2027-07 |
| NCT07410806Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Regimen I NUZ-001 | 2027-07-01 |
| NCT04220190Phase 3Rapa Therapeutics LLCRAPA-501 Therapy for ALS | 2027-07-01 |
Add all 41 to your calendar (.ics) → With an account.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a clinical trial to evaluate the safety, tolerability, and biological effect of LAM-002A in adults with C9ORF72-associated ALS (C9ALS).
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, biomarker-driven clinical trial evaluating the safety, tolerability, and biological effect of LAM-002A in approximately 12 adults with C9ORF72-associated ALS (C9ALS).
In Part A of the study, approximately twelve C9ALS participants will receive either standard of care plus LAM-002A or standard of care and placebo (randomized 2:1) for the first 12 weeks of the study (Core Study). LAM-002A will be administered as oral capsules 125 mg BID (250 mg total daily dose). The LAM-002A dose may be reduced to 100 mg BID (200 mg total daily dose) if expected gastrointestinal side effects develop.
Participants who complete the first 12 weeks of the Core Study will be eligible to receive active drug (LAM-002A capsules at maximum tolerated dose of 125 or 100 mg BID) for the remainder of the study (open-label extension [OLE]) up to Week 24.
In Part B of the study, participants who complete Part A Week 24 on study drug, will be offered the opportunity to opt-in to continue the open label extension for additional 36 weeks starting at the week 24 visit. Participants who elect not to roll over into the Treatment period B will complete the Day 168 visit, followed a final safety telephone call visit at week 28 to complete study participation. Participants who opt-in to the open label extension for an additional 36 weeks will have their end of study safety telephone call at week 64.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of C9ORF72-associated ALS with BOTH of the following:
Documentation of a clinical genetic test demonstrating the presence of a pathogenic repeat expansion in C9ORF72. If there is a strong clinical suspicion for C9ALS based on C9-positive family history and El Escorial Criteria consistent with a diagnosis of ALS, clinical testing for the C9ORF72 repeat expansion may be performed with study screening labs at the discretion of the Site Investigator (SI), medical monitor, and study sponsor.
AND
Exclusion Criteria:
unstable medical condition (other than ALS) that would pose a risk to the participant, according to the SI's judgment [e.g., cardiovascular instability, systemic infection, or clinically significant laboratory abnormality or (ECG) changes].
i. Serum (ALT) greater than 5 × (ULN).
ii. Serum aspartate aminotransferase (AST) greater than 5 × ULN.
iii. Serum greater than 1.5 × ULN.
c. Renal profile showing an estimated (eClCR) less than 30 mL/minute (with eClCR to be calculated by the method at the laboratory performing the serum creatinine test).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LAM-002A will be administered orally in five 25 mg capsules twice a day (250 mg total daily dose).
Drug: LAM-002A
Placebo matching LAM-002A will be administered orally in 5 capsules twice a day.
Other: Placebo
LAM-002A (apilimod dimesylate) is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, size 0.
Microcrystalline cellulose in Swedish orange, size 0 capsules.
Safety of LAM-002A: Occurrence of TEAEs and SAEs
Number of Participants with Treatment-Related Adverse Events (TEAEs) and Serious Adverse Events
Time frame: 24 Weeks
Tolerability of LAM-002A: Completion of Core Study Treatment
The percentage of participants who complete 12 weeks on study treatment during the Core Study.
Time frame: 12 Weeks
Plasma Pharmacokinetics of LAM-002A and Major Metabolites
The concentration of LAM-002A and its major metabolites (STA-5908, STA-5944, and STA-6048) in plasma.
Time frame: 24 Weeks
CSF Pharmacokinetics of LAM-002A and Major Metabolites
The concentration of LAM-002A and its major metabolites (STA-5908, STA-5944, and STA-6048) cerebral spinal fluid (CSF).
Time frame: 24 Weeks
Changes in Plasma Level of sGPNMB
Changes in plasma levels of the LAM-002A-induced biomarker, soluble glycoprotein nonmetastatic melanoma protein B (sGPNMB)
Time frame: 12 Weeks
Changes in CSF Level of sGPNMB
Changes in cerebrospinal fluid (CSF) levels of the LAM-002A-induced biomarker, soluble glycoprotein nonmetastatic melanoma protein B (sGPNMB)
Time frame: 12 Weeks
Tolerability of LAM-002A: Completion of Open-label Study Treatment
Secondary measures of tolerability will consider completion of 12 weeks on open-label study treatment during the OLE through study Week 24.
Time frame: 24 Weeks
Changes in ALSFRS-R Total Score and Domain Scores
Change in Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) total and domain scores. The assessment consists of 12 everyday tasks, grouped into four main domains. Each task is scored from 0 (complete loss of function) to 4 (normal ability). The total score is the sum of the domain scores (bulbar: 0-12 points; fine motor: 0-12 points; gross motor: 0-12 points; respiratory: 0-12 points). The maximum total score is 48 points, with the higher the score indicating better function.
Time frame: 24 Weeks
Percent Predicted Slow Vital Capacity
The percent predicted in slow vital capacity (SVC) over time. Predicted and Percent predicted values for slow vital capacity (SVC) were calculated using Quanjer Global Lung Initiative (GLI) equations based on participant age, sex, height at baseline, and self-reported race/ethnicity matched to GLI categories.
Time frame: 24 Weeks
Permanent Assisted Ventilation-free Survival
Number of participants that required permanent-assisted-ventilation (or died)
Time frame: 24 Weeks
Changes in ALS-CBS
Change in Amyotrophic Lateral Sclerosis Cognitive Behavioral Scale (ALS-CBS). Comprised of two sub-scores. The cognitive sub-score is rated 0-20 with the higher the score the better patient cognitive function. The behavioral sub-score was assessed by the caregiver and is rated 0-45 with the higher the score the better patient behavioral function.
Time frame: 24 Weeks
CSF Levels of NfL
Changes in cerebrospinal fluid (CSF) levels of the exploratory disease related biomarker, neurofilament light chain (NfL). Decreases in NfL are considered positive pharmacological effects of LAM-002A.
Time frame: 24 Weeks
Plasma Levels of NfL
Changes in plasma levels of the exploratory disease related biomarker, neurofilament light chain (NfL). Decreases in NfL are considered positive pharmacological effects of LAM-002A.
Time frame: 12 Weeks
CSF Levels of Poly (GP) Dipeptide Repeats
Changes in cerebrospinal fluid (CSF) levels of the exploratory disease related biomarker, Poly(GP) dipeptide repeats. Decreases in poly (GP) are considered positive pharmacological effects of LAM-002A.
Time frame: 24 Weeks
PBMC Levels of Poly (GP) Dipeptide Repeats
Changes in peripheral blood mononuclear cells (PBMC) levels of the exploratory disease related biomarker, Poly(GP) dipeptide repeats. Decreases in poly (GP) are considered positive pharmacological effects of LAM-002A.
Time frame: 24 Weeks
The study was conducted at four study centers who consented or screened at least one participant.
| Milestone | LAM-002A Weeks 1-24 and OLE (Part B and Part C) | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C) |
|---|---|---|
| Started | 10 | 5 |
| Completed treatment to week 12 | 9 | 5 |
| Completed treatment to week 24 | 7 | 3 |
| Completed | 8 | 3 |
| Not completed | 2 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Progressive disease | 1 | 1 |
| Milestone | LAM-002A Weeks 1-24 and OLE (Part B and Part C) | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C) |
|---|---|---|
| Started | 4 | 2 |
| Completed | 0 | 0 |
| Not completed | 4 | 2 |
| Withdrew: Study terminated by sponsor | 4 | 2 |
| Milestone | LAM-002A Weeks 1-24 and OLE (Part B and Part C) | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C) |
|---|---|---|
| Started | 3 | 1 |
| Completed | 0 | 0 |
| Not completed | 3 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Disease progression | 2 | 1 |
Number of Participants with Treatment-Related Adverse Events (TEAEs) and Serious Adverse Events
| Participants | LAM-002A Weeks 1-24 | Placebo Weeks 1-12 | LAM-002A Weeks 12-24 |
|---|---|---|---|
| Treatment Emergent Adverse Events (TEAEs) | 10 | 3 | 5 |
| Serious Adverse Events (SAEs) | 1 | 0 | 1 |
The percentage of participants who complete 12 weeks on study treatment during the Core Study.
| Participants | LAM-002A Weeks 1-24 | Placebo Weeks 1-12 |
|---|---|---|
| Tolerability of LAM-002A: Completion of Core Study Treatment | 9 | 5 |
The concentration of LAM-002A and its major metabolites (STA-5908, STA-5944, and STA-6048) in plasma.
| ng/mL | LAM-002A Weeks 1-24 | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 |
|---|---|---|
| LAM-002A Baseline (predose) | 0.10 ± 0.000 | 0.10 ± 0.000 |
| LAM-002A Week 2 (1 hour post dose) | 269.73 ± 196.302 | 0.10 ± 0.000 |
| LAM-002A Week 4 (1 hour post dose) | 213.80 ± 122.041 | 0.10 ± 0.000 |
| LAM-002A Week 8 (1 hour post dose) | 344.10 ± 184.700 | 0.18 ± 0.173 |
| LAM-002A Week 12 (1 hour post dose) | 283.13 ± 135.198 | 172.64 ± 149.986 |
| LAM-002A Week 24 (1 hour post dose) | 315.40 ± 131.386 | 153.83 ± 118.791 |
| STA-5908 Baseline (predose) | 0.10 ± 0.000 | 0.10 ± 0.000 |
| STA-5908 Week 2 (1 hour post dose) | 188.02 ± 136.417 | 0.10 ± 0.000 |
| STA-5908 Week 4 (1 hour post dose) | 175.47 ± 151.479 | 0.10 ± 0.000 |
| STA-5908 Week 8 (1 hour post dose) | 274.14 ± 159.777 | 0.13 ± 0.075 |
| STA-5908 Week 12 (1 hour post dose) | 214.93 ± 141.649 | 98.34 ± 99.581 |
| STA-5908 Week 24 (1 hour post dose) | 270.60 ± 124.025 | 109.60 ± 94.667 |
| STA-5944 Baseline (predose) | 0.10 ± 0.000 | 0.10 ± 0.000 |
| STA-5944 Week 2 (1 hour post dose) | 332.60 ± 219.078 | 0.10 ± 0.000 |
| STA-5944 Week 4 (1 hour post dose) | 335.49 ± 242.004 | 0.10 ± 0.000 |
| STA-5944 Week 8 (1 hour post dose) | 452.01 ± 286.689 | 0.18 ± 0.170 |
| STA-5944 Week 12 (1 hour post dose) | 391.81 ± 229.064 | 205.12 ± 195.581 |
| STA-5944 Week 24 (1 hour post dose) | 384.40 ± 202.858 | 226.70 ± 173.966 |
| STA-6048 Baseline (predose) | 0.10 ± 0.000 | 0.10 ± 0.000 |
| STA-6048 Week 2 (1 hour post dose) | 110.97 ± 89.947 | 0.10 ± 0.000 |
| STA-6048 Week 4 (1 hour post dose) | 116.36 ± 137.876 | 0.10 ± 0.000 |
| STA-6048 Week 8 (1 hour post dose) | 156.73 ± 99.335 | 0.11 ± 0.018 |
| STA-6048 Week 12 (1 hour post dose) | 118.83 ± 95.803 | 56.60 ± 53.608 |
| STA-6048 Week 24 (1 hour post dose) | 227.38 ± 151.576 | 68.53 ± 48.920 |
The concentration of LAM-002A and its major metabolites (STA-5908, STA-5944, and STA-6048) cerebral spinal fluid (CSF).
| ng/mL | LAM-002A Weeks 1-24 | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 |
|---|---|---|
| LAM-002A Baseline (predose) | 0.01 ± 0.000 | 0.01 ± 0.000 |
| LAM-002A Week 4 (1 hour post dose) | 1.50 ± 0.901 | 0.01 ± 0.000 |
| LAM-002A Week 8 (1 hour post dose) | 1.96 ± 1.159 | 0.01 ± 0.000 |
| LAM-002A Week 12 (1 hour post dose) | 1.63 ± 0.937 | 1.03 ± 1.024 |
| LAM-002A Week 24 (1 hour post dose) | 2.58 ± 2.000 | 1.81 ± 1.709 |
| STA-5908 Baseline (predose) | 0.01 ± 0.000 | 0.01 ± 0.000 |
| STA-5908 Week 4 (1 hour post dose) | 1.39 ± 1.134 | 0.01 ± 0.000 |
| STA-5908 Week 8 (1 hour post dose) | 1.98 ± 1.484 | 0.01 ± 0.000 |
| STA-5908 Week 12 (1 hour post dose) | 1.56 ± 1.484 | 0.55 ± 0.521 |
| STA-5908 Week 24 (1 hour post dose) | 2.21 ± 1.334 | 0.50 ± 0.478 |
| STA-5944 Baseline (predose) | 0.01 ± 0.000 | 0.01 ± 0.000 |
| STA-5944 Week 4 (1 hour post dose) | 1.07 ± 0.965 | 0.01 ± 0.000 |
| STA-5944 Week 8 (1 hour post dose) | 1.61 ± 1.499 | 0.01 ± 0.000 |
| STA-5944 Week 12 (1 hour post dose) | 1.26 ± 1.278 | 0.59 ± 0.603 |
| STA-5944 Week 24 (1 hour post dose) | 1.57 ± 1.001 | 0.47 ± 0.367 |
| STA-6048 Baseline (predose) | 0.01 ± 0.000 | 0.01 ± 0.000 |
| STA-6048 Week 4 (1 hour post dose) | 0.23 ± 0.250 | 0.01 ± 0.000 |
| STA-6048 Week 8 (1 hour post dose) | 0.36 ± 0.270 | 0.01 ± 0.000 |
| STA-6048 Week 12 (1 hour post dose) | 0.22 ± 0.251 | 0.02 ± 0.014 |
| STA-6048 Week 24 (1 hour post dose) | 0.68 ± 0.531 | 0.04 ± 0.029 |
Changes in plasma levels of the LAM-002A-induced biomarker, soluble glycoprotein nonmetastatic melanoma protein B (sGPNMB)
| pg/mL | LAM-002A Weeks 1-24 | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 |
|---|---|---|
| Baseline (pre-dose) | 17640.9 (13373.0 to 23270.7) | 18111.4 (12241.6 to 26795.9) |
| Week 2 (1 hour post dose) | 26431.5 (20037.0 to 34866.8) | 17638.7 (11922.1 to 26096.5) |
| Week 4 (1 hour post dose) | 29904.2 (22351.1 to 40009.6) | 17555.0 (11865.5 to 25972.7) |
| Week 8 (1 hour post dose) | 39358.2 (29632.4 to 52276.2) | 17961.8 (12140.4 to 26574.5) |
| Week 12 (1 hour post dose) | 40425.7 (30436.1 to 53694.0) | 17989.9 (12159.4 to 26616.2) |
Changes in cerebrospinal fluid (CSF) levels of the LAM-002A-induced biomarker, soluble glycoprotein nonmetastatic melanoma protein B (sGPNMB)
| pg/mL | LAM-002A Weeks 1-24 | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 |
|---|---|---|
| Baseline (pre-dose) | 2012.0 (1716.1 to 2358.9) | 1698.6 (1356.4 to 2127.2) |
| Week 4 (1 hour post dose) | 1819.7 (1548.6 to 2138.1) | 1693.3 (1352.1 to 2120.5) |
| Week 8 (1 hour post dose) | 1871.1 (1592.4 to 2198.5) | 1758.6 (1404.3 to 2202.3) |
| Week 12 (1 hour post dose) | 1990.0 (1693.7 to 2338.3) | 1821.1 (1454.2 to 2280.6) |
Secondary measures of tolerability will consider completion of 12 weeks on open-label study treatment during the OLE through study Week 24.
| Participants | LAM-002A Weeks 1-24 | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 |
|---|---|---|
| Tolerability of LAM-002A: Completion of Open-label Study Treatment | 7 | 3 |
Change in Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) total and domain scores. The assessment consists of 12 everyday tasks, grouped into four main domains. Each task is scored from 0 (complete loss of function) to 4 (normal ability). The total score is the sum of the domain scores (bulbar: 0-12 points; fine motor: 0-12 points; gross motor: 0-12 points; respiratory: 0-12 points). The maximum total score is 48 points, with the higher the score indicating better function.
| score on a scale | LAM-002A Weeks 1-24 | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 |
|---|---|---|
| Baseline ALFRS-R Bulbar Domain Score | 10.3 ± 2.21 | 8.4 ± 4.51 |
| Baseline ALFRS-R Fine Motor Domain Score | 9.6 ± 2.32 | 8.0 ± 3.39 |
| Baseline ALFRS-R Gross Motor Domain Score | 9.5 ± 2.07 | 10.0 ± 2.55 |
| Baseline ALFRS-R Respiratory Domain Score | 11.2 ± 1.23 | 11.6 ± 0.89 |
| Baseline ALFRS-R Total Score | 40.6 ± 5.02 | 38.0 ± 6.96 |
| Week 4 ALFRS-R Bulbar Domain Score | 10.4 ± 2.17 | 8.2 ± 4.76 |
| Week 4 ALFRS-R Fine Motor Domain Score | 9.1 ± 2.38 | 7.6 ± 3.78 |
| Week 4 ALFRS-R Gross Motor Domain Score | 8.8 ± 1.99 | 9.4 ± 3.13 |
| Week 4 ALFRS-R Respiratory Domain Score | 11.4 ± 0.70 | 11.2 ± 0.84 |
| Week 4 ALFRS-R Total Score | 39.7 ± 4.85 | 36.4 ± 9.13 |
| Week 8 ALFRS-R Bulbar Domain Score | 10.1 ± 3.18 | 8.2 ± 4.76 |
| Week 8 ALFRS-R Fine Motor Domain Score | 8.4 ± 2.07 | 7.6 ± 3.65 |
| Week 8 ALFRS-R Gross Motor Domain Score | 7.9 ± 2.62 | 9.0 ± 3.24 |
| Week 8 ALFRS-R Respiratory Domain Score | 11.4 ± 0.53 | 10.8 ± 1.64 |
| Week 8 ALFRS-R Total Score | 37.9 ± 6.49 | 35.6 ± 9.91 |
| Week 12 ALFRS-R Bulbar Domain Score | 9.7 ± 3.04 | 8.2 ± 4.76 |
| Week 12 ALFRS-R Fine Motor Domain Score | 8.1 ± 2.80 | 7.0 ± 3.67 |
| Week 12 ALFRS-R Gross Motor Domain Score | 7.6 ± 2.30 | 8.8 ± 3.63 |
| Week 12 ALFRS-R Respiratory Domain Score | 11.0 ± 1.66 | 10.6 ± 1.95 |
| Week 12 ALFRS-R Total Score | 36.3 ± 6.78 | 34.6 ± 9.02 |
| Week 24 ALFRS-R Bulbar Domain Score | 9.1 ± 3.52 | 8.7 ± 4.93 |
| Week 24 ALFRS-R Fine Motor Domain Score | 7.6 ± 2.88 | 5.0 ± 3.61 |
| Week 24 ALFRS-R Gross Motor Domain Score | 6.0 ± 1.20 | 7.0 ± 2.00 |
| Week 24 ALFRS-R Respiratory Domain Score | 11.0 ± 1.20 | 11.7 ± 0.58 |
| Week 24 ALFRS-R Total Score | 33.8 ± 6.92 | 32.3 ± 10.69 |
The percent predicted in slow vital capacity (SVC) over time. Predicted and Percent predicted values for slow vital capacity (SVC) were calculated using Quanjer Global Lung Initiative (GLI) equations based on participant age, sex, height at baseline, and self-reported race/ethnicity matched to GLI categories.
| percentage of predicted SVC | LAM-002A Weeks 1-24 | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 |
|---|---|---|
| Baseline | 78.0 ± 17.46 | 76.7 ± 15.83 |
| Week 4 | 81.6 ± 14.58 | 66.9 ± 22.05 |
| Week 8 | 81.6 ± 14.58 | 68.5 ± 22.00 |
| Week 12 | 81.6 ± 14.58 | 64.3 ± 24.95 |
| Week 24 | 75.1 ± 18.06 | 59.4 ± 17.95 |
Number of participants that required permanent-assisted-ventilation (or died)
| Participants | LAM-002A Weeks 1-24 | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 |
|---|---|---|
| Permanent Assisted Ventilation-free Survival | 0 | 1 |
Change in Amyotrophic Lateral Sclerosis Cognitive Behavioral Scale (ALS-CBS). Comprised of two sub-scores. The cognitive sub-score is rated 0-20 with the higher the score the better patient cognitive function. The behavioral sub-score was assessed by the caregiver and is rated 0-45 with the higher the score the better patient behavioral function.
| score on a scale | LAM-002A Weeks 1-24 | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 |
|---|---|---|
| Cognitive Scale Baseline | 16.8 ± 2.74 | 17.4 ± 1.14 |
| Cognitive Scale Week 8 | 15.8 ± 3.46 | 18.0 ± 1.83 |
| Cognitive Scale Week 12 | 15.9 ± 2.52 | 17.4 ± 1.34 |
| Cognitive Scale Week 24 | 16.6 ± 2.57 | 19.0 ± 1.00 |
| Behavioral Scale Baseline | 40.0 ± 7.26 | 44.0 ± 1.00 |
| Behavioral Scale Week 8 | 39.8 ± 3.76 | 42.0 ± 3.00 |
| Behavioral Scale Week 12 | 40.7 ± 3.08 | 39.8 ± 5.68 |
| Behavioral Scale Week 24 | 40.3 ± 0.58 | 38.0 ± 5.66 |
Changes in cerebrospinal fluid (CSF) levels of the exploratory disease related biomarker, neurofilament light chain (NfL). Decreases in NfL are considered positive pharmacological effects of LAM-002A.
| pg/mL | LAM-002A Weeks 1-24 | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 |
|---|---|---|
| Baseline (pre-dose) | 6706.826 ± 5697.3818 | 6301.775 ± 4539.1300 |
| Week 4 (1 hour post dose) | 6106.606 ± 3807.7290 | 6121.476 ± 2207.9686 |
| Week 8 (1 hour post dose) | 5979.763 ± 3021.3039 | 4915.784 ± 2286.8341 |
| Week 12 (1 hour post dose) | 6372.683 ± 3606.4654 | 6875.761 ± 3260.2480 |
| Week 24 (1 hour post dose) | 10041.440 ± 7355.1333 | 2932.091 ± 227.6043 |
Changes in plasma levels of the exploratory disease related biomarker, neurofilament light chain (NfL). Decreases in NfL are considered positive pharmacological effects of LAM-002A.
| pg/mL | LAM-002A Weeks 1-24 | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 |
|---|---|---|
| Baseline (pre-dose) | 102 (20.4 to 140) | 71.9 (54.8 to 181) |
| Week 2 (1 hour post dose) | 108 (33.1 to 265) | 79.9 (56.2 to 188) |
| Week 4 (1 hour post dose) | 108 (33.1 to 265) | 76.6 (54.8 to 210) |
| Week 8 (1 hour post dose) | 132 (44.9 to 227) | 58.1 (53.0 to 230) |
| Week 12 (1 hour post dose) | 142 (42.5 to 211) | 62.0 (49.2 to 251) |
Changes in cerebrospinal fluid (CSF) levels of the exploratory disease related biomarker, Poly(GP) dipeptide repeats. Decreases in poly (GP) are considered positive pharmacological effects of LAM-002A.
| Dipeptide Repeats | LAM-002A Weeks 1-24 | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 |
|---|---|---|
| Baseline | 436.99 ± 360.750 | 851.80 ± 502.302 |
| Week 4 | 174.38 ± 172.814 | 694.04 ± 339.209 |
| Week 8 | 148.40 ± 118.061 | 690.17 ± 434.694 |
| Week 12 | 111.77 ± 96.820 | 699.98 ± 281.230 |
| Week 24 | 161.04 ± 167.306 | 407.10 ± 400.276 |
Changes in peripheral blood mononuclear cells (PBMC) levels of the exploratory disease related biomarker, Poly(GP) dipeptide repeats. Decreases in poly (GP) are considered positive pharmacological effects of LAM-002A.
| Dipeptide Repeats | LAM-002A Weeks 1-24 | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 |
|---|---|---|
| Baseline | 236.80 ± 158.286 | 272.45 ± 89.363 |
| Week 4 | 183.97 ± 93.514 | 274.75 ± 253.200 |
| Week 8 | 254.92 ± 209.838 | 400.75 ± 270.411 |
| Week 12 | 225.14 ± 138.802 | 260.75 ± 182.497 |
| Week 24 | 95.55 ± 73.369 | 275.75 ± 197.283 |
Collected over From Baseline through Week 24. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LAM-002A Weeks 1-24 | 0/10 (0%) | 1/10 (10%) | 10/10 (100%) |
| Placebo Weeks 1-12 | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| LAM-002A Weeks 12-24 | 1/5 (20%) | 1/5 (20%) | 5/5 (100%) |
| Event | LAM-002A Weeks 1-24 | Placebo Weeks 1-12 | LAM-002A Weeks 12-24 |
|---|---|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/10 | 0/5 | 1/5 |
| PancreatitisGastrointestinal disorders | 1/10 | 0/5 | 0/5 |
| Event | LAM-002A Weeks 1-24 | Placebo Weeks 1-12 | LAM-002A Weeks 12-24 |
|---|---|---|---|
| FallInjury, poisoning and procedural complications | 6/10 | 2/5 | 1/5 |
| DiarrhoeaGastrointestinal disorders | 4/10 | 0/5 | 1/5 |
| NauseaGastrointestinal disorders | 4/10 | 0/5 | 0/5 |
| ContusionInjury, poisoning and procedural complications | 4/10 | 0/5 | 0/5 |
| COVID-19Infections and infestations | 4/10 | 0/5 | 1/5 |
| HeadacheNervous system disorders | 4/10 | 1/5 | 0/5 |
| ConstipationGastrointestinal disorders | 3/10 | 0/5 | 0/5 |
| Procedural painInjury, poisoning and procedural complications | 3/10 | 0/5 | 0/5 |
| Decreased appetiteMetabolism and nutrition disorders | 3/10 | 0/5 | 0/5 |
| VomitingGastrointestinal disorders | 2/10 | 0/5 | 1/5 |
| Age, Categorical(Participants) | LAM-002A Weeks 1-24 and OLE (Part B and Part C) | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 5 | 12 |
| >=65 years | 3 | 0 | 3 |
| Age, Continuous(Years) | LAM-002A Weeks 1-24 and OLE (Part B and Part C) | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C) | Total |
|---|---|---|---|
| Mean | 62.3 ± 5.50 | 60.0 ± 2.74 | 61.5 ± 4.78 |
| Sex: Female, Male(Participants) | LAM-002A Weeks 1-24 and OLE (Part B and Part C) | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C) | Total |
|---|---|---|---|
| Female | 5 | 1 | 6 |
| Male | 5 | 4 | 9 |
| Race (NIH/OMB)(Participants) | LAM-002A Weeks 1-24 and OLE (Part B and Part C) | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 10 | 5 | 15 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | LAM-002A Weeks 1-24 and OLE (Part B and Part C) | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 10 | 5 | 15 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Weight(kg) | LAM-002A Weeks 1-24 and OLE (Part B and Part C) | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C) | Total |
|---|---|---|---|
| Mean | 74.04 ± 14.414 | 72.54 ± 9.486 | 73.54 ± 12.641 |
| Height(cm) | LAM-002A Weeks 1-24 and OLE (Part B and Part C) | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C) | Total |
|---|---|---|---|
| Mean | 173.06 ± 10.268 | 173.46 ± 9.698 | 173.21 ± 9.688 |
| BMI(kg/m2) | LAM-002A Weeks 1-24 and OLE (Part B and Part C) | Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C) | Total |
|---|---|---|---|
| Mean | 25.59 ± 3.656 | 24.18 ± 3.315 | 25.09 ± 3.478 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2021 to primary completion in Jan 2023, 12 months.
Results were first posted in Sep 2026, 3 years 8 months after primary completion.
Of 36 industry-sponsored phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 12 months is below that.
Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apilimod Dimesylate Capsule
Amyotrophic Lateral Sclerosis →
IRulya Therapeutics Inc.